FDA clears SeaStar Medical trial enrollment
SeaStar Medical says the NEUTRALIZE-AKI pivotal trial is evaluating its SCD therapy in 339 adults with acute kidney injury in the ICU receiving continuous renal replacement therapy.
SeaStar Medical says the NEUTRALIZE-AKI pivotal trial is evaluating its SCD therapy in 339 adults with acute kidney injury in the ICU receiving continuous renal replacement therapy.